As of 2025-05-22, the EV/EBITDA ratio of LogicBio Therapeutics Inc (LOGC) is -1.97. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LOGC's latest enterprise value is 145.80 mil USD. LOGC's TTM EBITDA according to its financial statements is -74.00 mil USD. Dividing these 2 quantities gives us the above LOGC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 13.5x | 13.4x |
| Forward P/E multiples | 19.0x - 21.2x | 20.1x |
| Fair Price | (50.93) - (35.46) | (44.53) |
| Upside | -732.7% - -540.5% | -653.2% |
| Date | EV/EBITDA |
| 2025-05-22 | -1.86 |
| 2025-05-21 | -1.97 |
| 2025-05-20 | -1.95 |
| 2025-05-19 | -1.90 |
| 2025-05-16 | -1.88 |
| 2025-05-15 | -1.75 |
| 2025-05-14 | -1.73 |
| 2025-05-13 | -1.84 |
| 2025-05-12 | -1.78 |
| 2025-05-09 | -1.71 |
| 2025-05-08 | -1.73 |
| 2025-05-07 | -1.67 |
| 2025-05-06 | -1.59 |
| 2025-05-05 | -1.58 |
| 2025-05-02 | -1.59 |
| 2025-05-01 | -1.61 |
| 2025-04-30 | -1.65 |
| 2025-04-29 | -1.65 |
| 2025-04-28 | -1.64 |
| 2025-04-25 | -1.70 |
| 2025-04-24 | -1.63 |
| 2025-04-23 | -1.59 |
| 2025-04-22 | -1.56 |
| 2025-04-21 | -1.52 |
| 2025-04-17 | -1.50 |
| 2025-04-16 | -1.50 |
| 2025-04-15 | -1.58 |
| 2025-04-14 | -1.44 |
| 2025-04-11 | -1.45 |
| 2025-04-10 | -1.50 |
| 2025-04-09 | -1.56 |
| 2025-04-08 | -1.38 |
| 2025-04-07 | -1.41 |
| 2025-04-04 | -1.41 |
| 2025-04-03 | -1.56 |
| 2025-04-02 | -1.65 |
| 2025-04-01 | -1.56 |
| 2025-03-31 | -1.59 |
| 2025-03-28 | -1.58 |
| 2025-03-27 | -1.63 |
| 2025-03-26 | -1.66 |
| 2025-03-25 | -1.76 |
| 2025-03-24 | -1.78 |
| 2025-03-21 | -1.78 |
| 2025-03-20 | -1.79 |
| 2025-03-19 | -1.77 |
| 2025-03-18 | -1.77 |
| 2025-03-17 | -1.79 |
| 2025-03-14 | -1.79 |
| 2025-03-13 | -1.78 |